First Chinese Rare Disease Biotech IPO To Spark Interest In Less Travelled Path?
CanBridge public listing is expected to generate much needed funding and spotlights a largely untapped but challenging segment.
You may also be interested in...
Amid China’s increasingly inward-looking and dual circulation economic policies, the Beijing Winter Olympics provide rare insight into policymakers’ handling of a global event.
Few drug patent infringement cases go to court in China, where a murky and lengthy process deters many from pursuing litigation. But a newly enacted Patent Law with patent linkage provisions is spurring a rise in infringement lawsuits, with one recent case involving a major Japanese pharma firm underscoring the remaining challenges.
Gene therapies for conditions ranging from hemophilia to retinal diseases are blossoming in China and the race in which the winner may take all is on. Driven by ready investors, the field is on the cusp of becoming the latest innovation battleground in the country, while some developers are already moving ahead in the US.